Shuttle Pharmaceuticals Holdings, Inc. Profile
Industry
Drug Manufacturers - Specialty & GenericSector
HealthcareNumber of Employees
8Shuttle Pharmaceuticals's Business Model
Shuttle Pharmaceuticals Holdings, Inc., through its subsidiary, Shuttle Pharmaceuticals, Inc., focuses on the discovery, development, and commercialization of drugs for sensitizing cancers to radiation therapy. Its products in clinical stage include Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and soft tissue sarcomas; and Doranidazole, an injectable hypoxic cell radiation sensitizer for treatment of pancreatic, lung, and liver cancers. The company was founded in 2012 and is based in Rockville, Maryland.
About Shuttle Pharmaceuticals
Website: https://www.shuttlepharma.com
CEO (Chief Executive Officer): Dr. Anatoly Dritschilo M.D.
IPO date: 2022-08-31
Contact
Country: US
Address: One Research Court
City: Rockville
State: MD
Phone: 240 403 4212
Zip Code: 20850
Other
CIK: 0001757499
ISIN: US8256932034
CUSIP: 825693203
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
